Therapy Areas: Respiratory
AstraZeneca completes transfer of Eklira, Duaklir rights
5 January 2022 -

Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) confirmed on Wednesday that it has completed the transfer of its global rights to the inhaled respiratory medicines Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol).

AstraZeneca received USD270m from Covis Pharma Group for the rights to the two dry powder treatments. It will also receive payments in respect of certain ongoing development costs related to the medicines.

Eklira and Duaklir are used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Eklira is a long-acting muscarinic antagonist (LAMA), which is marketed in the US as Tudorza and in some countries as Bretaris.

Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA). It is marketed in some countries as Brimica.

Both medicines are delivered via the breath-actuated multi-dose dry powder inhaler Genuair (Pressair in the US). AstraZeneca licensed the global rights to both products from Almirall S.A. in 2014.



Related Headlines